Gilead Sciences, Inc. (NASDAQ:GILD) Position Raised by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 904,153 shares of the biopharmaceutical company’s stock after purchasing an additional 73,290 shares during the period. Mawer Investment Management Ltd. owned 0.07% of Gilead Sciences worth $61,085,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Parnassus Investments CA increased its holdings in shares of Gilead Sciences by 21.2% in the first quarter. Parnassus Investments CA now owns 13,074,555 shares of the biopharmaceutical company’s stock valued at $849,976,000 after buying an additional 2,288,767 shares in the last quarter. Miller Howard Investments Inc. NY purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at $93,386,000. First Trust Advisors LP grew its holdings in shares of Gilead Sciences by 77.8% during the 2nd quarter. First Trust Advisors LP now owns 2,825,707 shares of the biopharmaceutical company’s stock valued at $190,905,000 after acquiring an additional 1,236,379 shares in the last quarter. State of Tennessee Treasury Department grew its holdings in shares of Gilead Sciences by 122.8% during the 1st quarter. State of Tennessee Treasury Department now owns 987,411 shares of the biopharmaceutical company’s stock valued at $64,191,000 after acquiring an additional 544,218 shares in the last quarter. Finally, Sanders Capital LLC grew its holdings in shares of Gilead Sciences by 5.0% during the 1st quarter. Sanders Capital LLC now owns 11,291,933 shares of the biopharmaceutical company’s stock valued at $793,701,000 after acquiring an additional 539,793 shares in the last quarter. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:GILD traded down $0.66 during mid-day trading on Friday, hitting $63.56. The company’s stock had a trading volume of 205,922 shares, compared to its average volume of 6,097,710. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $80.60 billion, a price-to-earnings ratio of 10.33, a P/E/G ratio of 3.01 and a beta of 1.16. The stock has a fifty day moving average of $65.65 and a 200-day moving average of $65.77.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.54 billion. During the same period in the prior year, the firm earned $1.91 earnings per share. Gilead Sciences’s revenue was down 2.8% compared to the same quarter last year. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 6.65 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be issued a $0.63 dividend. The ex-dividend date is Thursday, September 12th. This represents a $2.52 annualized dividend and a yield of 3.96%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

Several research firms have recently commented on GILD. JPMorgan Chase & Co. restated a “buy” rating and set a $85.00 price target on shares of Gilead Sciences in a report on Wednesday, July 31st. Goldman Sachs Group lowered shares of Gilead Sciences from a “neutral” rating to a “sell” rating and cut their target price for the stock from $70.00 to $60.00 in a research report on Tuesday, May 28th. Morgan Stanley set a $82.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a research report on Monday, July 15th. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, June 5th. Finally, Cowen reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, May 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $82.29.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 608 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $64.35, for a total value of $39,124.80. Following the sale, the executive vice president now directly owns 27,198 shares in the company, valued at $1,750,191.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Brett A. Pletcher sold 7,200 shares of the stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the sale, the executive vice president now owns 34,398 shares in the company, valued at $2,238,277.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,624 shares of company stock worth $907,479. Company insiders own 0.20% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: How do CD ladders protect against rising interest rates?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.